BIOMAT Database Logo BIOMAT Database Logo

Comparison of 150 mg nizatidine BID or 300 mg at bedtime, and 150 mg ranitidine BID in the treatment of gastric ulcer--an 8-week randomized, double-blind multicentre study. 1990

F Di Mario, and G Battaglia, and R Naccarato, and A D'Angelo, and A Saggioro, and G L Da Broi, and P Vezzadini, and G Bianchi Porro
Istituto di Medicina Interna, Cattedra Malattie Apparato Digerente, Padova.

One hundred and one active gastric ulcer patients concluded an 8-week, randomized, double-blind multicentre study, planned with the aim to compare the effectiveness of a new H2 blocker, nizatidine, with ranitidine. Thirty-three patients received 300 mg nizatidine at bedtime, 34,150 mg nizatidine b.i.d. and 34,150 mg ranitidine b.i.d. The three groups were well matched for the common clinical parameters. After 4 weeks, healing rates were 51.5% (confidence intervals 95%: 34.1-68.9%), 61.8% (41.2-82.4%), 76.5% (51-102%), respectively. At this check point ranitidine showed a significantly better outcome than did 300 mg nizatidine at bedtime (p less than 0.05). After 8 weeks, healing rates were 81.8% (54.1-109.5%), 88.2% (58.7-117.7%) and 88.2% (58.7-117.7%); these differences were not statistically significant. Age, sex, ulcer symptoms, alcohol and cigarette consumption, concomitant treatments, ulcer size and site and length of ulcer history were all found not to influence ulcer healing. Pain relief and antacid consumption were comparable in the three treatment groups. No clinically significant unwanted effects were recorded throughout the study. Nizatidine can, in our opinion, be successfully used in the treatment of active gastric ulcer.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011899 Ranitidine A non-imidazole blocker of those histamine receptors that mediate gastric secretion (H2 receptors). It is used to treat gastrointestinal ulcers. AH-19065,Biotidin,N (2-(((5-((Dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine,Ranisen,Ranitidin,Ranitidine Hydrochloride,Sostril,Zantac,Zantic,AH 19065,AH19065,Hydrochloride, Ranitidine
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006635 Histamine H2 Antagonists Drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood. Antihistaminics, H2,H2 Receptor Blockader,Histamine H2 Antagonist,Histamine H2 Blocker,Histamine H2 Receptor Antagonist,Histamine H2 Receptor Antagonists,Histamine H2 Receptor Blockader,Histamine H2 Receptor Blockaders,Antagonists, Histamine H2,Blockaders, Histamine H2 Receptor,H2 Receptor Blockaders,Histamine H2 Blockers,Receptor Antagonists, Histamine H2,Receptor Blockaders, H2,Antagonist, Histamine H2,Blockader, H2 Receptor,Blockaders, H2 Receptor,Blocker, Histamine H2,Blockers, Histamine H2,H2 Antagonist, Histamine,H2 Antagonists, Histamine,H2 Antihistaminics,H2 Blocker, Histamine,H2 Blockers, Histamine,Receptor Blockader, H2
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

F Di Mario, and G Battaglia, and R Naccarato, and A D'Angelo, and A Saggioro, and G L Da Broi, and P Vezzadini, and G Bianchi Porro
Ranitidine 300 mg at bedtime is effective for gastric ulcers: a 12-wk, multicenter, randomized, double-blind, placebo-controlled comparison. The Ranitidine 300 mg HS Gastric Ulcer Study Group.
July 1993, The American journal of gastroenterology,
F Di Mario, and G Battaglia, and R Naccarato, and A D'Angelo, and A Saggioro, and G L Da Broi, and P Vezzadini, and G Bianchi Porro
Acute treatment of reflux oesophagitis: a multicentre study to compare 150 mg ranitidine twice daily with 300 mg ranitidine at bedtime.
April 1989, Alimentary pharmacology & therapeutics,
F Di Mario, and G Battaglia, and R Naccarato, and A D'Angelo, and A Saggioro, and G L Da Broi, and P Vezzadini, and G Bianchi Porro
A double-blind controlled trial of ranitidine 300 mg nocte and ranitidine 150 mg b.i.d. in the short-term treatment of gastric ulcer.
February 1986, International journal of clinical pharmacology, therapy, and toxicology,
F Di Mario, and G Battaglia, and R Naccarato, and A D'Angelo, and A Saggioro, and G L Da Broi, and P Vezzadini, and G Bianchi Porro
[Nizatidine versus ranitidine in the treatment of acute duodenal ulcer. Comparison of 300 mg nizatidine and 300 mg ranitidine in a single evening dose].
July 1989, Fortschritte der Medizin,
F Di Mario, and G Battaglia, and R Naccarato, and A D'Angelo, and A Saggioro, and G L Da Broi, and P Vezzadini, and G Bianchi Porro
300 mg nizatidine at night versus 300 mg ranitidine at night in patients with duodenal ulcer. A multicentre trial in Europe.
January 1987, Scandinavian journal of gastroenterology. Supplement,
F Di Mario, and G Battaglia, and R Naccarato, and A D'Angelo, and A Saggioro, and G L Da Broi, and P Vezzadini, and G Bianchi Porro
Twenty-four-hour control of gastric acidity by twice-daily doses of placebo, nizatidine 150 mg, nizatidine 300 mg, and ranitidine 300 mg.
January 1993, Journal of clinical pharmacology,
F Di Mario, and G Battaglia, and R Naccarato, and A D'Angelo, and A Saggioro, and G L Da Broi, and P Vezzadini, and G Bianchi Porro
Comparison between ranitidine 150 mg b.d. and ranitidine 300 mg nocte in the treatment of duodenal ulcer.
July 1986, International journal of clinical pharmacology, therapy, and toxicology,
F Di Mario, and G Battaglia, and R Naccarato, and A D'Angelo, and A Saggioro, and G L Da Broi, and P Vezzadini, and G Bianchi Porro
Gastric ulcer: a double blind comparison of 800 mcg misoprostol versus 300 mg ranitidine.
October 1987, Hepato-gastroenterology,
F Di Mario, and G Battaglia, and R Naccarato, and A D'Angelo, and A Saggioro, and G L Da Broi, and P Vezzadini, and G Bianchi Porro
Acute treatment of duodenal ulcer: a multicentre study to compare ranitidine 150 mg twice daily with ranitidine 300 mg once at night.
September 1986, Gut,
F Di Mario, and G Battaglia, and R Naccarato, and A D'Angelo, and A Saggioro, and G L Da Broi, and P Vezzadini, and G Bianchi Porro
Nizatidine versus placebo in active benign gastric ulcer disease: an eight-week, multicenter, randomized, double-blind comparison. The Nizatidine Benign Gastric Ulcer Disease Study Group.
September 1992, Clinical pharmacology and therapeutics,
Copied contents to your clipboard!